What Is the Optimal Induction Therapy for Younger Fit Patients With AML? Hugo F. Fernandez Acute Myeloid Leukemias (H Erba, Section Editor) 30 July 2016 Pages: 327 - 332
Transient Abnormal Myelopoiesis and AML in Down Syndrome: an Update Neha BhatnagarLaure NizeryIrene Roberts Myeloproliferative Disorders (C Harrison, Section Editor) Open access 10 August 2016 Pages: 333 - 341
Investigation and Management of Erythrocytosis Mary Frances McMullin Myeloproliferative Disorders (C Harrison, Section Editor) 16 July 2016 Pages: 342 - 347
The Use of Anagrelide in Myeloproliferative Neoplasms, with Focus on Essential Thrombocythemia Gunnar BirgegÄrd Myeloproliferative Disorders (C Harrison, Section Editor) Open access 06 August 2016 Pages: 348 - 355
How We Identify and Manage Patients with Inadequately Controlled Polycythemia Vera Andreas ReiterClaire Harrison Myeloproliferative Disorders (C Harrison, Section Editor) 19 February 2016 Pages: 356 - 367
Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You Marco RuellaCarl H. June CART and Immunotherapy (M Ruella, Section Editor) 30 July 2016 Pages: 368 - 384
Treatment of Childhood Acute Lymphoblastic Leukemia: Prognostic Factors and Clinical Advances Lynda M. VroomanLewis B. Silverman Acute Lymphocytic Leukemias (K Ballen, Section Editor) 08 August 2016 Pages: 385 - 394